Milton C. Ault III - 30 Jul 2025 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ALZN
Reported as of: 30 Jul 2025
Net transaction value: -$295,532
SEC form: 4
Accepted by SEC: 01 Aug 2025, 16:30:19 UTC
Prior SEC filing: 31 Jul 2025
Next SEC filing: 25 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Milton C. Ault, III

Key filing fact

Milton C. Ault III filed Form 4 for Alzamend Neuro, Inc. (ALZN) on 01 Aug 2025.

Key facts

This page summarizes Milton C. Ault III's Form 4 filing for Alzamend Neuro, Inc. (ALZN).
4 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 01 Aug 2025, 16:30.

Change

Previous filing in this sequence was filed on 31 Jul 2025.
Current net transaction value: -$295,532.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001212502 Primary reporting owner

AULT MILTON C III

Relationship: Director, 10%+ Owner
Address: 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 190, LAS VEGAS
Signature: /s/ Milton C. Ault, III
Signature date: 01 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALZN transaction

Common Stock

Conversion of derivative security

Transaction value: $232,000
Shares: +100,000
Change %: +265%
Price: $2.32
Shares after: 137,709
Date: 30 Jul 2025
Ownership: By Ault Lending, LLC
Footnotes: F1, F2

ALZN transaction

Common Stock

Sale

Transaction value: $73,982
Shares: -29,449
Change %: -21%
Price: $2.51
Shares after: 108,260
Date: 30 Jul 2025
Ownership: By Ault Lending, LLC
Footnotes: F2, F3

ALZN transaction

Common Stock

Sale

Transaction value: $221,550
Shares: -100,000
Change %: -92%
Price: $2.22
Shares after: 8,260
Date: 31 Jul 2025
Ownership: By Ault Lending, LLC
Footnotes: F2, F4

ALZN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,843
Date: 30 Jul 2025
Ownership: Direct

ALZN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 11,068
Date: 30 Jul 2025
Ownership: By Ault Life Sciences, Inc.
Footnotes: F5

ALZN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 61
Date: 30 Jul 2025
Ownership: By Ault Life Sciences Fund, LLC
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALZN transaction Derivative

Series B Convertible Preferred Stock

Conversion of derivative security

Transaction value: $232,000
Shares: -232
Change %: -13%
Price: $1000.00
Shares after: 1,535
Date: 30 Jul 2025
Ownership: By Ault Lending, LLC
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $2.32
Footnotes: F2, F7, F8

ALZN holding Derivative

Common Stock Purchase Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 13,556
Date: 30 Jul 2025
Ownership: By Ault Lending, LLC
Underlying class: Common Stock
Underlying amount: 13,556
Exercise price: $108.00
Footnotes: F2

ALZN holding Derivative

Common Stock Purchase Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,667
Date: 30 Jul 2025
Ownership: By Ault Lending, LLC
Underlying class: Common Stock
Underlying amount: 8,667
Exercise price: $108.00
Footnotes: F2

ALZN holding Derivative

Common Stock Purchase Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,111
Date: 30 Jul 2025
Ownership: By Ault Lending, LLC
Underlying class: Common Stock
Underlying amount: 1,111
Exercise price: $108.00
Footnotes: F2

ALZN holding Derivative

Common Stock Purchase Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12
Date: 30 Jul 2025
Ownership: By Hyperscale Data, Inc.
Underlying class: Common Stock
Underlying amount: 12
Exercise price: $4050.00
Footnotes: F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Represents shares of common stock received upon conversion of Series B convertible preferred stock ("Series B Preferred").

Footnote F2

Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.

Footnote F3

The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.5122. The range of sales prices on the transaction date was $2.4047 to $2.6367 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

Footnote F4

The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.2155. The range of sales prices on the transaction date was $2.1628 to $2.2511 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

Footnote F5

Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.

Footnote F6

Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

Footnote F7

The Conversion Price of the Series B Preferred is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and Limitations of the Series B Convertible Voting Preferred Stock.

Footnote F8

The shares of Series B Preferred have no expiration date.

Footnote F9

Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by HSD.